keyword
MENU ▼
Read by QxMD icon Read
search

Diffuse large b cell

keyword
https://www.readbyqxmd.com/read/28806244/lymphoma-causing-gastrosplenic-fistula-revealed-by-fdg-pet-ct
#1
Trent P Wang, Mohan Doss, Jeffrey L Tokar, Sanjay Reddy, Stefan K Barta, Jian Q Yu
A 73-year-old man presented with fatigue and weight loss. He had CT-proven splenic mass with fistulous connection to the greater curvature of the stomach, which suggested abscess. FDG PET/CT confirmed gastrosplenic fistula in addition to active lymph nodes in the gastrohepatic ligament and epigastric region. Pathological examination after the biopsy of the spleen was consistent with diffuse large B-cell lymphoma. Chemotherapy was administered with close clinical follow-up and resulted in the resolution of fistula without requirement for surgery...
August 12, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28804923/hypopigmented-mycosis-fungoides-with-large-cell-transformation-in-a-child
#2
Dinesh Pradhan, Jaroslaw J Jedrych, Jonhan Ho, Oleg E Akilov
Hypopigmented mycosis fungoides (HMF) is the most common variant of mycosis fungoides (MF) in children. Large-cell transformation in HMF has never been reported. Herein we report a case of HMF in an 8-year-old boy who presented with a 6-year history of hypopigmented patches on the bilateral arms, lower back, buttocks, posterior thighs, and lower legs. Biopsy revealed an abnormal CD8(+) epidermotropic T-cell infiltrate consistent with the diagnosis of MF. The T-cell clonality study was positive. The patient was started on narrowband ultraviolet B (NBUVB) phototherapy and topical steroids...
August 14, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28803861/long-duration-complete-remissions-of-diffuse-large-b-cell-lymphoma-after-anti-cd19-chimeric-antigen-receptor-t%C3%A2-cell-therapy
#3
James N Kochenderfer, Robert P T Somerville, Tangying Lu, James C Yang, Richard M Sherry, Steven A Feldman, Lori McIntyre, Adrian Bot, John Rossi, Norris Lam, Steven A Rosenberg
T cells expressing anti-CD19 chimeric antigen receptors (CARs) can induce complete remissions (CRs) of diffuse large B cell lymphoma (DLBCL). The long-term durability of these remissions is unknown. We administered anti-CD19 CAR T cells preceded by cyclophosphamide and fludarabine conditioning chemotherapy to patients with relapsed DLBCL. Five of the seven evaluable patients obtained CRs. Four of the five CRs had long-term durability with durations of remission of 56, 51, 44, and 38 months; to date, none of these four cases of lymphomas have relapsed...
July 13, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28803429/patients-with-primary-breast-and-primary-female-genital-tract-diffuse-large-b-cell-lymphoma-have-a-high-frequency-of-myd88-and-cd79b-mutations
#4
Xin-Xin Cao, Jian Li, Hao Cai, Wei Zhang, Ming-Hui Duan, Dao-Bin Zhou
This study is to retrospectively evaluate the prevalence of MYD88 and CD79B mutations and the clinicopathologic characteristics of patients with primary diffuse large B cell lymphoma (DLBCL) of the female genital tract and breast. The characteristics, treatments, and outcomes of 19 patients diagnosed with primary DLBCL of the female genital tract and breast, who had formalin-fixed and paraffin-embedded tissues obtained from diagnostic samples diagnosed between January 2004 and June 2016, were analyzed retrospectively...
August 12, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28802500/primary-cutaneous-b-cell-lymphomas
#5
REVIEW
Charity B Hope, Laura B Pincus
B-cell lymphomas represent approximately 20% to 25% of primary cutaneous lymphomas. Within this group, most cases (>99%) are encompassed by 3 diagnostic entities: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type. In this article, the authors present clinical, histopathologic, immunophenotypic, and molecular features of each of these entities and briefly discuss the rarer intravascular large B-cell lymphoma.
September 2017: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/28802087/variant-histology-igd-and-cd30-expression-in-low-risk-pediatric-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-report-from-the-children-s-oncology-group
#6
Ramona Vesna Untanu, Jason Back, Burton Appel, Qinglin Pei, Lu Chen, Allen Buxton, David C Hodgson, Peter F Ehrlich, Louis S Constine, Cindy L Schwartz, Robert E Hutchison
BACKGROUND: Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL. PROCEDURE: One hundred sixty-eight cases of localized NLPHL were examined for histologic variants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored categorically as 0 = 0, 1 ≤ 25%, and 2 > 25% of the sample...
August 12, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28800008/epstein-barr-virus-infection-can-be-a-secondary-event-in-b-cell-lymphomas-a-review-of-338-cases-and-a-novel-finding-of-zonal-eber-tumor-cells-showing-features-of-progression-from-underlying-ebv-negative-lymphoma
#7
Ira J Miller
Cases of B-cell lymphoma over an 8-year interval with diagnosis of EBER positivity were retrieved from archives and reviewed for classification and pattern of Epstein Barr Virus (EBV) expression. Of 46 cases that were EBV early RNA (EBER)+ by in situ hybridization staining, 7 had nonuniform staining among the neoplastic cells. Four of those cases showed a uniform admixture of EBER+ and EBER- tumor cells, compatible with the prevailing theory of episomal EBV loss with cell replication. Three cases of lymphomas showed a partial and zonal pattern and other features suggest that EBV infection occurred after the lymphoma was already established...
August 9, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28798271/the-search-for-surrogate-endpoints-in-trials-in-diffuse-large-b-cell-lymphoma-the-surrogate-endpoints-for-aggressive-lymphoma-project
#8
Daniel J Sargent, Qian Shi, Christopher R Flowers, Norbert Schmitz, Thomas M Habermann, Jocelyne Flament, Tommy Fu, Bertrand Coiffier
No abstract text is available yet for this article.
August 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28798034/fdg-pet-ct-in-lymphoma-has-imaging-directed-personalized-medicine-become-a-reality
#9
Sally F Barrington, Peter Wm Johnson
Positron emission tomography with computed tomography (PET-CT) using (18)F- fluorodeoxyglucose (FDG) is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the five-point 'Deauville scale', have enabled PET to become a surrogate for treatment success/failure in common lymphoma subtypes. This review summarizes the key evidence from clinical trials that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy...
August 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28797193/exposure-response-evaluations-of-venetoclax-efficacy-and-safety-in-patients-with-non-hodgkin-lymphoma
#10
Apurvasena Parikh, Sathej Gopalakrishnan, Kevin J Freise, Maria E Verdugo, Rajeev M Menon, Sven Mensing, Ahmed Hamed Salem
Exposure-response analyses were performed for a venetoclax monotherapy study in 106 patients with varying subtypes of non-Hodgkin lymphoma (NHL) (NCT01328626). Logistic regression, time-to-event, and progression-free survival (PFS) analyses were used to evaluate the relationship between venetoclax exposure, NHL subtype and response, PFS, or occurrence of serious adverse events. Trends for small increases in the probability of response with increasing venetoclax exposures were identified, and became more evident when assessed by NHL subtype...
August 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28796588/obinutuzumab-or-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-in-previously-untreated-diffuse-large-b-cell-lymphoma
#11
Umberto Vitolo, Marek Trněný, David Belada, John M Burke, Angelo Michele Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian Flinn, Xiaonan Hong, Won Seog Kim, Antonio Pinto, Yuan-Kai Shi, Yoichi Tatsumi, Mikkel Z Oestergaard, Michael Wenger, Günter Fingerle-Rowson, Olivier Catalani, Tina Nielsen, Maurizio Martelli, Laurie H Sehn
Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy is the standard of care in previously untreated diffuse large B-cell lymphoma (DLBCL). Obinutuzumab (G) is a glycoengineered, type II, anti-CD20 monoclonal antibody. GOYA was a randomized phase III study that compared G-CHOP with R-CHOP in patients with previously untreated advanced-stage DLBCL. Methods Patients (N = 1,418) were randomly assigned to receive eight 21-day cycles of G (n = 706) or R (n = 712), plus six or eight cycles of CHOP...
August 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28796066/a-new-diagnostic-marker-for-differentiating-multicentric-gliomas-from-multiple-intracranial-diffuse-large-b-cell-lymphomas-on-18f-fdg-pet-images
#12
Kai Wang, Xiaobin Zhao, Qian Chen, Di Fan, Zhen Qiao, Song Lin, Tao Jiang, Jianping Dai, Lin Ai
Intracranial gliomas and lymphomas may share similar radiological manifestations, while the treatment strategies for them are different. The aim of the study was to investigate the diagnostic value of fluorine-18-fluoro-2-deoxy-D-glucose (F-FDG) positron emission computed tomography (PET) for differentiation of multicentric gliomas and intracranial multiple diffuse large B-cell lymphomas (DLBCLs) as a study of diagnostic accuracy.A total of 32 patients with multiple intracranial tumors visualized on contrast-enhanced magnetic resonance imaging (MRI) were retrospectively evaluated...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28794358/the-clinical-and-hormonal-characteristics-of-primary-adrenal-lymphomas-the-necessity-of-early-detection-of-adrenal-insufficiency
#13
Ko Harada, Kosuke Kimura, Masaya Iwamuro, Tomohiro Terasaka, Yoshihisa Hanayama, Eisei Kondo, Eiko Hayashi, Tadashi Yoshino, Fumio Otsuka
Objective To analyze the clinical and endocrine characteristics of patients with primary adrenal lymphoma. Patients We retrospectively reviewed the cases of five patients with primary adrenal lymphoma who were treated in our hospital between April 2004 and March 2015. We investigated the characteristics of the clinical and pathological findings, treatment, prognosis and complications of adrenal insufficiency. Results Adrenal insufficiency, which was confirmed by the laboratory data at the initial presentation, was observed in two cases...
August 10, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28791996/-a-case-of-primary-diffuse-large-b-cell-lymphoma-of-the-brain
#14
S N Sovgirya, N I Vynnyk, A K Prylutsky, O A Tikhonova, I V Kornilova, I I Starchenko
The paper describes a case of primary extranodal diffuse large B-cell lymphoma of the cerebral hemispheres, which was regarded as an inflammatory disease of the brain during life and diagnosed only posthumously in the microscopically examination of the autopsy material by immunohistochemical studies.
2017: Arkhiv Patologii
https://www.readbyqxmd.com/read/28791403/complex-analysis-of-the-tp53-tumor-suppressor-in-mantle-cell-and-diffuse-large-b-cell-lymphomas
#15
Lenka Zlamalikova, Mojmir Moulis, Barbora Ravcukova, Kvetoslava Liskova, Jitka Malcikova, David Salek, Jiri Jarkovsky, Miluse Svitakova, Renata Hrabalkova, Jan Smarda, Jana Smardova
Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL...
August 8, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28789937/grade-3-follicular-lymphoma-outcomes-in-the-rituximab-era
#16
Moaath Mustafa Ali, Lisa Rybicki, Laila Nomani, Basel Rouphail, Robert M Dean, Brian T Hill, Deepa Jagadeesh, Brad Pohlman, Eric D Hsi, Mitchell R Smith
BACKGROUND: Follicular lymphoma (FL) is heterogeneous. Although FL Grade 3B (FL3B) is treated as aggressive FL (aggFL), an optimal approach to FL Grade 3A (FL3A) remains unclear because few data exist on clinical outcomes on the basis of subclassification of FL Grade 3 (FL3) since the introduction of rituximab. We report outcomes of FL3 in the rituximab era. PATIENTS AND METHODS: We identified and analyzed a retrospective cohort of 53 patients with FL3A, 3B, and FL Grade 3 with areas of diffuse large B-cell lymphoma (DLBCL)...
July 13, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28782131/diffuse-large-b-cell-lymphoma-associated-with-chronic-inflammation-arising-within-atrial-myxoma-aggressive-histologic-features-but-indolent-clinical-behaviour
#17
Jinhai Yan, Luo Donglan, Fen Zhang, Jiao He, Su Yao, Luo Xinlan, Fangping Xu, Yu Chen, Lingyi Fu, Jie Xu, Yanhui Liu
AIMS: Primary cardiac lymphoma (PCL) is a rare neoplasm. PCL is fatal, unless it is diagnosed and treated early. Recently, a small number of cases of diffuse large B cell lymphoma (DLBCL) arising within atrial myxoma have been reported in immunocompetent patients and showed aggressive histologic features but an indolent clinical behaviour. METHODS AND RESULTS: We presented four unusual cases of Epstein-Barr virus (EBV)-positive DLBCL arising within atrial myxoma with detailed clinical, histologic, immunophenotypic and genotypic features in immunocompetent patients, and reviewed the literature for 11 similar cases...
August 7, 2017: Histopathology
https://www.readbyqxmd.com/read/28781919/b-cell-lymphoma-presenting-as-multiple-nerve-sheath-tumors
#18
Jason Milton, Julie Renner, Victor Awuor
BACKGROUND: Diffuse Large B-cell Lymphoma (DLBCL) is the most common form of Non-Hodgkin lymphoma (NHL), accounting for 25-30 percent of cases in the United States.1 Extranodal sites are involved in approximately 40% of cases of DLBCL. CASE DESCRIPTION: In this report, we discuss the case of a patient with extranodal DLBCL within the cervical nerve roots that underwent surgical intervention due to the presence of cervical radiculopathy. CONCLUSION: The diagnosis of DLBCL was surprising given the appearance of the masses on MRI being similar to that of a neurofibroma or schwannoma...
2017: Surgical Neurology International
https://www.readbyqxmd.com/read/28776574/increased-myc-copy-number-is-an-independent-prognostic-factor-in-patients-with-diffuse-large-b-cell-lymphoma
#19
Andrés E Quesada, L Jeffrey Medeiros, Parth A Desai, Pei Lin, Jason R Westin, Huda M Hawsawi, Peng Wei, Guilin Tang, Adam C Seegmiller, Nishitha M Reddy, C Cameron Yin, Wei Wang, Jie Xu, Roberto N Miranda, Zhuang Zuo, Shaoying Li
Patients with double-hit or triple-hit lymphoma have a significantly worse prognosis compared to patients with diffuse large B-cell lymphoma without MYC rearrangement. However, the prognostic importance of extra copies of MYC, BCL2, or BCL6 has not been fully explored. We studied 663 patients with de novo diffuse large B-cell lymphoma in whom the status of MYC/8q24, BCL2/18q21, and BCL6/3q27 were assessed by fluorescence in situ hybridization. Cases of double or triple extra copy lymphoma were defined by the presence of increased MYC copies and increased BCL2 and/or BCL6 copies or rearrangement...
August 4, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28775232/silencing-heme-oxygenase-1-increases-the-sensitivity-of-abc-dlbcl-cells-to-histone-deacetylase-inhibitor-in-vitro-and-in-vivo
#20
Zhen Zhou, Qin Fang, Dan Ma, Nana Zhe, Mei Ren, Bingqing Cheng, Peifan Li, Ping Liu, Xiaojing Lin, Sishi Tang, Xiuying Hu, Yudan Liao, Yaming Zhang, Tingting Lu, Jishi Wang
Heme oxygenase-1 (HO-1) can promote tumor growth and reinforce the resistance of diffuse large B-cell lymphoma (DLBCL) cells to chemotherapeutic drug vincristine. We herein found that HO-1 protein expression was higher in high-risk DLBCL patients than in low-risk ones. Silencing HO-1 gene expression resisted vorinostat-induced apoptosis and arrested cell cycle in the G0/G1 phase of LY-10 cells. Western blot, co-immunoprecipitation and chromatin immunoprecipitation assays confirmed that the possible mechanisms may be increased cleaved caspase-3 protein expression, decreased phospho-histone deacetylase 3 protein expression, and activated histone acetylation of P27Kip1 promoter...
July 28, 2017: Oncotarget
keyword
keyword
2698
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"